Ocugen, Inc. (OCGN) stock
OCGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$0.74−0.02 (-2.31%)
Close on Nov 18, 2026Market cap $250.67MP/E –Yield –
Ocugen shares outstanding
Diluted shares outstanding: the weighted share count used for earnings per share, adjusted for stock splits.
Ocugen's shares outstanding was 339M at Jun 30, 2026. For fiscal 2023 it was 244M, up 13.9% from the year before. The highest annual figure on record is 244M in fiscal 2023.
Annual shares outstanding
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2023 | Dec 31, 2023 | 244M | +13.9% |
| FY2022 | Dec 31, 2022 | 215M | +10.0% |
| FY2021 | Dec 31, 2021 | 195M | +73.8% |
| FY2020 | Dec 31, 2020 | 112M | +707.8% |
| FY2019 | Dec 31, 2019 | 14M | +180.1% |
| FY2018 | Dec 31, 2018 | 5M | +31.3% |
| FY2017 | Dec 31, 2017 | 4M | +57.5% |
| FY2016 | Dec 31, 2016 | 2M | +8.8% |
| FY2015 | Dec 31, 2015 | 2M | +762.5% |
| FY2014 | Dec 31, 2014 | 0M | – |
Quarterly shares outstanding
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | 339M | +31.6% |
| Q1 FY2026 | Mar 31, 2026 | 328M | +27.3% |
| Q2 FY2025 | Jun 30, 2025 | 292M | +13.8% |
| Q1 FY2025 | Mar 31, 2025 | 292M | +13.8% |
| Q2 FY2024 | Jun 30, 2024 | 257M | +8.0% |
| Q1 FY2024 | Mar 31, 2024 | 257M | +14.1% |
| Q4 FY2023 | Dec 31, 2023 | 257M | +16.6% |
| Q3 FY2023 | Sep 30, 2023 | 256M | +18.4% |
| Q2 FY2023 | Jun 30, 2023 | 238M | +10.4% |
| Q1 FY2023 | Mar 31, 2023 | 226M | +9.6% |
| Q4 FY2022 | Dec 31, 2022 | 220M | +10.5% |
| Q3 FY2022 | Sep 30, 2022 | 217M | +9.0% |
| Q2 FY2022 | Jun 30, 2022 | 216M | +10.4% |
| Q1 FY2022 | Mar 31, 2022 | 206M | +10.4% |
| Q4 FY2021 | Dec 31, 2021 | 199M | +16.8% |
| Q3 FY2021 | Sep 30, 2021 | 199M | +40.4% |
| Q2 FY2021 | Jun 30, 2021 | 196M | +134.1% |
| Q1 FY2021 | Mar 31, 2021 | 186M | +254.0% |
| Q4 FY2020 | Dec 31, 2020 | 171M | +2561.7% |
| Q3 FY2020 | Sep 30, 2020 | 142M | +2233.6% |
| Q2 FY2020 | Jun 30, 2020 | 84M | +1584.0% |
| Q1 FY2020 | Mar 31, 2020 | 53M | +960.9% |
| Q3 FY2019 | Sep 30, 2019 | 6M | +29.2% |
| Q2 FY2019 | Jun 30, 2019 | 6M | -99.9% |
| Q1 FY2019 | Mar 31, 2019 | 5M | -99.9% |
| Q4 FY2018 | Dec 31, 2018 | 5M | +23.9% |
| Q3 FY2018 | Sep 30, 2018 | 5M | +32.0% |
| Q2 FY2018 | Jun 30, 2018 | 4.79B | +129454.1% |
| Q1 FY2018 | Mar 31, 2018 | 4.61B | +126166.8% |
| Q4 FY2017 | Dec 31, 2017 | 4M | +35.6% |
| Q3 FY2017 | Sep 30, 2017 | 4M | +69.6% |
| Q2 FY2017 | Jun 30, 2017 | 4M | – |
| Q1 FY2017 | Mar 31, 2017 | 4M | – |
| Q4 FY2016 | Dec 31, 2016 | 3M | – |
| Q3 FY2016 | Sep 30, 2016 | 2M | – |
See a number that looks wrong?